Price T Rowe Associates Inc Autolus Therapeutics PLC Transaction History
Price T Rowe Associates Inc
- $816 Billion
- Q1 2024
A detailed history of Price T Rowe Associates Inc transactions in Autolus Therapeutics PLC stock. As of the latest transaction made, Price T Rowe Associates Inc holds 5,488,986 shares of AUTL stock, worth $18.6 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
5,488,986
Previous 3,001,208
82.89%
Holding current value
$18.6 Million
Previous $19.3 Million
81.19%
% of portfolio
0.0%
Previous 0.0%
Shares
2 transactions
Others Institutions Holding AUTL
# of Institutions
123Shares Held
168MCall Options Held
411KPut Options Held
67.6K-
Syncona Portfolio LTD Guernsey, Channel Islands, X021.3MShares$72.2 Million90.76% of portfolio
-
Blackstone Inc New York, NY20.5MShares$69.2 Million0.54% of portfolio
-
Deep Track Capital, LP Greenwich, CT15.3MShares$51.6 Million3.22% of portfolio
-
Avoro Capital Advisors LLC New York, NY12.3MShares$41.7 Million0.95% of portfolio
-
Wellington Management Group LLP Boston, MA10.8MShares$36.4 Million0.01% of portfolio
About Autolus Therapeutics plc
- Ticker AUTL
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 90,909,800
- Market Cap $307M
- Description
- Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which...